Iqvia Holdings Inc. SEC filings IQV
Iqvia Holdings Inc. has 1,000 filings in SEC EDGAR's recent list, going back to Dec 11, 2013. Its latest annual report, Form ARS, was filed on Feb 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Oct 27, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 27, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Feb 27, 2026 | — |
| DEF 14A | Proxy statement | Feb 27, 2026 | Apr 23, 2026 |
| DEFA14A | Additional proxy material | Feb 28, 2025 | — |
| DEF 14A | Proxy statement | Feb 28, 2025 | Apr 24, 2025 |
| PRE 14A | Preliminary proxy statement | Feb 18, 2025 | Apr 24, 2025 |
| DEFA14A | Additional proxy material | Feb 23, 2024 | — |
| DEF 14A | Proxy statement | Feb 23, 2024 | Apr 16, 2024 |
| DEFA14A | Additional proxy material | Feb 27, 2023 | — |
| DEF 14A | Proxy statement | Feb 27, 2023 | — |
| PRE 14A | Preliminary proxy statement | Feb 17, 2023 | — |
| DEFA14A | Additional proxy material | Mar 28, 2022 | — |
| DEFA14A | Additional proxy material | Feb 28, 2022 | — |
| DEF 14A | Proxy statement | Feb 28, 2022 | Apr 12, 2022 |
| PRE 14A | Preliminary proxy statement | Feb 18, 2022 | Apr 12, 2022 |
| DEFA14A | Additional proxy material | Mar 23, 2021 | — |
| DEFA14A | Additional proxy material | Feb 26, 2021 | — |
| DEF 14A | Proxy statement | Feb 26, 2021 | Apr 13, 2021 |
| PRE 14A | Preliminary proxy statement | Feb 16, 2021 | Dec 31, 2020 |
| DEFA14A | Additional proxy material | Feb 18, 2020 | — |
| DEF 14A | Proxy statement | Feb 18, 2020 | Apr 6, 2020 |
| DEFA14A | Additional proxy material | Feb 21, 2019 | — |
| DEF 14A | Proxy statement | Feb 21, 2019 | Apr 9, 2019 |
| DEFA14A | Additional proxy material | Mar 1, 2018 | — |
| DEF 14A | Proxy statement | Mar 1, 2018 | Apr 10, 2018 |
| DEFA14A | Additional proxy material | Feb 23, 2017 | — |
| DEF 14A | Proxy statement | Feb 22, 2017 | Apr 6, 2017 |
| DEFA14A | Additional proxy material | Mar 21, 2016 | — |
| DEF 14A | Proxy statement | Mar 21, 2016 | May 5, 2016 |
| DEFA14A | Additional proxy material | Mar 23, 2015 | — |
| DEF 14A | Proxy statement | Mar 23, 2015 | May 7, 2015 |
| DEF 14A | Proxy statement | Mar 31, 2014 | May 8, 2014 |
Showing 31 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- IQV (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Durham, NC
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1478242
- Former names
- Quintiles IMS Holdings, Inc. (until Nov 3, 2017); Quintiles Transnational Holdings Inc. (until Sep 22, 2016)
Other Services-Commercial Physical & Biological Research companies
- Incyte Corp INCY
- Medpace Holdings, Inc. MEDP
- Charles River Laboratories International, Inc. CRL
- Icon PLC ICLR
- Absci Corp ABSI
- OmniAb, Inc. OABI
- NRC Health NRC
- Maxcyte, Inc. MXCT
All 17 Services-Commercial Physical & Biological Research companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.